SlideShare una empresa de Scribd logo
1 de 89
Descargar para leer sin conexión
RETINOBLASTOMA
Dr. Pavan Naik
HISTORY
 First mentioned by Petras Pawius in Amsterdam -1597.
 James Wardrop- scottish surgeon first recommended
enucleation for saving lives - 1809.
 Verhoeff -origin from undifferentiated retinal cells,
named retinoblastoma in 1900’s.
 American Ophthalmology Society first adopted the term
retinoblastoma in 1926.
INTRODUCTION
 Primary malignant neoplasm of the retina that
arises from immature retinal cells
 It is the most common primary intraocular
malignancy of childhood in all racial groups
 Seventh MC tumor of childhood
 Unifocal/multifocal.
 Unilateral (70%) or bilateral (30%).
 Sporadic (94%) or familial (6%).
 Non hereditary (50-60%) or hereditary (40-
50%).
EPIDEMIOLOGY
 Cumulative lifetime incidence-1 in 15000
 Annual incidence –highest in first few months of life
 Yearly incidence decreases steadily
 Extremely low by 6 years of age.
 Rarely diagnosed congenitally or even within the first
3 months of life, except in familial cases.
 Median age at the time of diagnosis is approximately
12 months
 B/l retinoblastoma (12 months )>18m in u/l case
 Retinoblastoma affects boys and girls with equal
frequency and has no known racial predilection.
Frequency is shown as a function of age at diagnosis in subgroups of
unilateral versus bilateral disease.
INHERITANCE
 60–70% of retinoblastoma – unilateral
 30–40% are bilateral.
 In unilateral cases, only a single tumor is usually
present in the affected eye.
 In bilateral cases, multifocal tumors in both eyes are
the rule. Retinoblastoma is generally a sporadic
condition (i.e., no previously affected family members
exist).
 Sporadic form of retinoblastoma are affected
unilaterally.
 A small number -have a prior family history of
retinoblastoma-one of the parents is probably a
survivor of the disease.
 Transmission of the disease in such families follows
genetic rules of autosomal dominant inheritance.
Retinoblastoma
GENETICS
 Loss or inactivation of both normal alleles of the
retinoblastoma gene
 DNA sequence localized to a small segment of the
long arm (the q14 region) of chromosome 13
 The timing of the loss or inactivation of the two
normal alleles
 germinal (i.e., can be inherited by the offspring of an
affected person)
 somatic (i.e., cannot be inherited by the offspring of
an affected person)
 In germinal retinoblastoma- at least one normal allele
must be lost or inactivated prior to the first mitotic
division of embryogenesis
 Sperm or the egg contains defective DNA from an affected
or carrier parent or develops that defect by means of
spontaneous mutation prior to fertilization.
 In somatic retinoblastoma, both alleles are present and
active beyond the stage of the fertilized egg- but
subsequent mutations occur to delete or inactivate
both alleles in at least one immature retinal cell
(retinoblast).
For retinoblastoma to occur both the allels have to be
deleted
 If only one allel is deleted it is called 13q deletion
syndrome
Retinoblastoma
 In germinal mutaion , which is inherited ,
 First hit occurs before fertilisation & affects all types
of cell
 2nd hit occurs in somatic retinal cells leads to RB.
 2nd ry tumours like osteosarcoma are seen in familial
cases
 But in sporadic mutation both hits occurs during
development of retina , so it affects only retina , no
2nd ry tumours…
Individuals who inherit a mutation in the retinoblastoma gene are
heterozygous for the mutation in all cells of the body. The
“second hit” to the remaining normal copy of the gene occurs in
a developing retinal cell and leads to tumor formation
MOLECULAR PATHOGENESIS
 RB1 protein: cell cycle regulator, checkpoint between G1
& S-phase.
 Key factor in RB protien functioning is the
phosphorylation status.
 Normally unphosphorylated and suppresses entry into S-
phase by binding to E2F (transcription apparatus).
 Phosphorylation by cyclin/cdk’s abolishes inhibition &
causes dissociation of E2F which binds to DNA &
promotes progression through cell cycle.
Retinoblastoma
Retinoblastoma
CLINICAL MANIFESTATIONS
MANIFESTATION PERCENTAGE
LEUCOCORIA 56%
STRABISMUS 20%
RED PAINFUL EYE 7%
POOR VISION 5%
ASYMPTOMATIC 3%
ORBITAL CELLULITIS 3%
UNILATERAL MYDRIASIS 2%
HETEROCHROMIA IRIDID 1%
HYPHEMA 1%
CLINICAL MANIFESTATIONS
9. Proptosis of eye
LEUCOCORIA
PATTERNS OF GROWTH
Retinoblastoma
CLINICAL MANIFESTATIONS
 Clinical presentation depends on the stage of the
disease
 Early likely to be missed- unless IDO is performed
 Translucent white fluffy retinal mass
 Strabismus- if tumor involves macula/reduced visual
acuity
 Moderately advanced-leucocoria reflection of light by
white mass in the fundus
THREE MANIFESTATIONS
 Endophytic: grows in to vitreous cavity. Yellow white
mass fills vitreous cavity & vitreous seeds. Retinal
vessels –not seen on the surface
 Exophytic: tumor towards subretinal space. Retinal
detachment, retinal vessels are seen over tumor
 Diffuse infiltrating tumor: diffusely involve retina
placoid thickness of the retina. Older children delay
in diagnosis
 Advanced- proptosis secondary to optic nerve/ orbital
extension
 Orbital extension-scleral emissary veins
 Atypical manifestations:
-pseudohypopyon
-spontaneous hyphema
-vitreous hemorrhage
-phthisis bulbli
-preseptal/orbital cellulits
ROUTES OF SPREAD
PRESENTATION
 White round oval dome shaped retinal masses
 Attract retinal BVs
 Very small tumors - Translucent thickenings
 Larger tumors- non rhegmatogenous RD
 Tumors – extend via RPE- exophytic
- into vitreous - endophytic
-generalised thickening-Infiltrating
Retinoblastoma
 Ocassionally stops progressing-Retinoma
 Severe necrosis-Phthisis
Typical appearance of intraretinal retinoblastoma. Opaque, yellow-white macular
tumor fed and drained by dilated, tortuous retinal blood vessels.
RETINOMA-spontaneously arrested retinoblastoma
Limited vascularity
Greyish-white
Speckled
Surrounding chorio-retinal atrophy
RPE hypertrophy
PATHOLOGY
 Malignant neuroepithelial cells (retinoblasts)- arise within the immature
retina
 The retinoblasts -large basophilic nucleus and scanty cytoplasm.
 Cellular necrosis & intralesional calcification- larger tumors.
 Tissue differentiation occurs,- producing Flexner-Wintersteiner
rosettes or Homer Wright rosettes
 Photoreceptor differentiation of individual retinoblasts (fleurettes) may
also be observed
 Retinoblastoma - tendency to invade the optic nerve and choroid -
extend out of the globe via either the optic nerve or the scleral emissary
canals.
 Retinomas show such tumors to be composed entirely of benign-
appearing neuronal cells with photoreceptor differentiation, most
notably in the form of fleurettes.
 Pseudorosettes-tumor cells around Blood vessels
PATHOLOGY Flexner Wintersteiner
rosettes
-columnar cells around a
central lumen
-also seen in
medulloepithelioma
Homer Wright
-rosettes around a central
neuromuscular core
-neuroblastoma,
medulloepithelioma,
medulloblastomas
Fleurettes
Tumor cells with pear
shaped eosinophilic
processes projecting through
DIFFERENTIAL DIAGNOSIS
Differential Diagnosis of Leukokoria
Coats’ disease
Persistent hyperplastic primary vitreous
Ocular toxocariasis
Cicatricial retinopathy of prematurity
Familial exudative vitreoretinopathy
Incontinentia pigmenti retinopathy
Norrie’s disease
Differential Diagnosis of Vitreous Seeds
Pars planitis (intermediate uveitis)
Microbial endophthalmitis or retinitis
Leukemic infiltration
Differential Diagnosis of Discrete Retinal Tumors
Astrocytoma of retina
Medulloepithelioma
Retinal capillary hemangioma
LEUCOCORIA
TO BE CONTINUED IN NEXT CLASS
STAGING
DAIGNOSIS
TREATMENT
Retinoblastoma
Retinoblastoma
Retinoblastoma
Retinoblastoma
DIAGNOSIS
 ULTRASONOGRAPHY
 >10-15mm, multiple foci of calcification
 Shadows the sclera & orbital soft tissue
 On reducing the gain-reflection persist
 Demonstrates a mass more echogenic than vitreous on B
scan highly reflective intrinsic echoes of fine
calcifications-Ascan
 RD in exophytic tumors
 Accuracy-80% limited by vitreous opacities & RD
 Limited evaluation of medial and lateral extension
 Colour Doppler: displays normal & tumor vasculature &
differentiates subretinal or choroidalh’he from neoplasms
B-scan ultrasonography of retinoblastoma. Solid,
posterior intraocular mass contains strong particulate
reflections attributable to intralesional calcification.
INDIRECT OPHTHALMOSCOPY
 Dilated fundus examination under anaesthesia
 IOP and anterior segment-neovascularisation,
pseudohypopyon, hyphema and signs of inflammation
 Bilateral fundus examination-360◦ scleral depression
 Ret Cam: wide angle fundus camera –documenting and
monitoring response
CT SCAN
 Bright on CT scan
 Infiltrating Retinoblastoma-tumor multicentricity , extensive
seeding into vitreous
MRI
 Most useful for evaluating sellar/parasellar
 Rule out- ectopic intracranial RB
 Studying optic nerve & soft tissues
Computed tomography of bilateral intraocular retinoblastoma.
Intraocular masses appear bright because of intralesional calcification.
Retinoblastoma
FFA
 Not usually performed
 Rapid filling of feeder vessel-intraretinal vasculature-
draining of efferent vein
 Intralesional capillaries-leak fluoroscein
SYSTEMIC EVALUATON
 Germinal retinoblastoma have a strong tendency to
develop non-retinoblastoma malignancies
 Primary nonretinoblastoma intracranial malignancy -
either a pineoblastoma or an ectopic intracranial
retinoblastoma- most common neoplasm -somnolence,
headache, and other neurological symptoms.
 Central nervous system -solid tumor that involves the
suprasellar or parasellar regions of the brain
 Ophthalmoscopy frequently reveals papilledema-
referred to as trilateral retinobloma, seed the
cerebrospinal fluid and thereby spawn implantation
tumors along the spinal cord. This malignancy is
usually fatal
Sarcomas of bone and soft tissues- most
frequent nonretinoblastoma malignancies
Oculo-orbital external beam radiation therapy-
< age of 1 year appears-increase the
likelihood that such tumors will occur in the
field.
Syndrome of multiple congenital anomalies
attributed to a major deletion (13q deletion
syndrome by karyotype analysis.
BASELINE SYSTEMIC EVALUATION IN
RETINOBLASTOMA
 Complete pediatric history and physical
examination
 Blood for complete blood count (CBC)
 MRI or CT of brain, especially in bilateral or familial cases
to look for ectopic intracranial retinoblastoma
 Lumbar puncture for cerebrospinal fluid analysis[∗]
 Bone marrow aspiration or biopsy[∗]
 Bone scan[∗]
Retinoblastoma
INTERNATIONAL CLASSIFICATION (SHIELDS)
 Group A Small tumor
Retinoblastoma <3mm in size in basal
dimension/thickness
 Group B Larger tumor
Retinoblastoma>3mm basal diameter/ thickness
Macular location<3mm to foveola
Juxtapapillary location <1.5mm to the disc
Clear subretinal fluid<3mm from the margin
 Group C Focal seeds
c1-subretinal seeds<3mm
c2 –vitreous seeds <3mm
c3-both subretinal and vitreous seeds
 Group D Diffuse seeds
D1-subretinal seeds>3mm
D2-vitreous seeds >3mm
D3-Both
 Group E Extensive Retinoblastoma
occupying>50% of the globe
neovascular glaucoma
opaque media-hhge-
AC/PC/Subretnal space
Invasion of postlaminar optic nerve/
choroid/sclera/orbit/AC
STAGING
Retinoblastoma
PROGNOSTIC FACTORS
MANAGEMENT
 Primary goal-save life
 Salvage of the organ and function-secondary and tertiary
 Multidisciplinary approach
 Individualised –depends on
1. Age
2. Laterality
3. Location
4. Staging
5. Systemic condition
6. Overall progression
7. Cost effectiveness
CURRENT SUGGESTED PROTOCOL
 A Intraocular tumor- international classification group-A-C
U/L or B/L
1. Focal-cryotherapy/transpupillary thermotherapy
tumors<3mm in visually non crucial areas
2. Standard 6 cycle chemoreduction and focal therapy for
larger tumors and in visually crucial areas
3. Defer focal therapy for 6 cycles for tumors in macular
and juxtapapillary areas-transpupillary
thermotherapy/plaque RT in juxtapapillary and macula
4. Focal therapy small residual tumors, plaque RT, EBRT
-> 12 months.large.B/L and enucleation if U/L
 B. Intraocular tumor, Group D U/L or B/L
1. High dose chemotherapy/aggressive focal therapy
2. Periocular carboplatin –vitreous seeds
3. Primary enucleation-U/L- esp with no visual
prognosis
 C. Group E U/L or B/L
1. Primary enucleation
2. Evaluate histopathology for high risk factors
 D. High risk factors on HPE- Stage 2
1. Baseline systemic evaluation for metastasis
2. Standard 6 cycle adjuvant therapy
3. High dose adjuvant chemotherapy + orbital EBRT-
with scleral infiltration, extraocular extension, optic
nerve extension
 E. Extraocular tumor-Stage 3A
1. Baseline systemic evaluation for metastases
2. High dose chemotherapy-3-6 cycles followed by
enucleation/extended enucleation, EBRT, high
dose chemo 12 cycles
 F. Regional LN metastasis Stage 3B
1. Baseline evaluation for systemic metastasis
2. Neck dissection, high dose chemotherapy for 6
cycles, followed by EBRT and high dose
chemotherapy-12 cycles
 G. Hematogenous /CNS metastasis-Stage 4
1. Palliative therapy
2. High dose chemotherapy –BM rescue
3. High dose chemotherapy- intrathecal
chemotherapy for CNS metastases
TREATMENT
 TREATMENT OPTIONS FOR INTRAOCULAR
RETINOBLASTOMA
Intravenous chemotherapy
Enucleation
Radiation therapy
• External beam radiation therapy
• Plaque radiotherapy
Laser therapy
• Photocoagulation
• Transpupillary thermotherapy (TTT)
Cryotherapy
Observation (for spontaneously arrested retinoblastoma,
retinoma)
CHEMOTHERAPY
 Chemotherapy is currently the primary therapeutic
option -bilateral retinoblastoma.
 Initial treatment - unilateral disease -affected eye is salvageable.
 Most common chemotherapeutic regimen -a combination of
carboplatin, etoposide or a related drug, and vincristine (CEV
regimen). In some centers, cyclosporine is added to this regimen
to reduce the multidrug resistance that occurs in many
retinoblastomas.
 Chemotherapy must be supervised by a pediatric oncologist who
is familiar with the side effects and complications of the drugs
and can monitor the child closely during treatment.
 Cyclic treatment every 3–4 weeks for six or more cycles.
 Most intraocular retinoblastoma lesions (including intravitreal and
 Partially regressed tumors -still viable following the
second cycle of chemotherapy / any new tumors during
the course of chemotherapy must be treated by
obliterative local therapies such as cryotherapy, laser
therapy, and episcleral plaque radiation therapy.
 Periocular carboplatin injections are currently being
evaluated as an adjunct to intravenous chemotherapy in
selected cases.
 Residual or recurrent intravitreal and subretinal seeds
following chemotherapy and local treatments usually
require external beam radiation therapy if the eye is to be
salvaged.
Chemotherapy for
retinoblastoma. (A)
Pretreatment appearance of
macular retinoblastoma. (B)
Same lesion after two cycles of
chemotherapy using vincristine,
etoposide, and carboplatin.
ENUCLEATION
 Enucleation remains an important therapeutic option for this
disease.
 Children who have unilateral advanced intraocular disease.
 Enucleation is sometimes recommended for both eyes in
children who have bilateral far-advanced disease not amenable
to any eye-preserving therapy and for the more severely affected
eye in markedly asymmetrical bilateral cases.
 If enucleation is performed, the ophthalmic surgeon should
attempt to obtain a long section of the optic nerve during surgery.
 The principal route of exit of tumor cells from the
eye is along the optic nerve. Prior pathological
studies have shown that enucleation is usually
curative in retinoblastoma if an optic nerve section
longer than 5 mm is obtained with the globe.[15] If
possible, the ophthalmic surgeon should attempt
to obtain an optic
nerve section 10–15 mm long in every case.
 Insertion of an orbital implant at the time of
enucleation appears to be appropriate except
when there is a strong likelihood of residual tumor
in the orbit..
SPECIAL CONSIDERATIONS FOR
ENUCLEATION
 A Minimal manipulation
 B Avoid perforation of the eye
 C Harvest long >15 mm optic nerve stump
 D inspect the enucleated eye for macroscopic
extraocular extension & optic nerve involvement
 E Harvest fresh tissue for genetic studies
 F Place a primary implant
 G Avoid biointegrated implant if postoperative
radiotherapy is necessary
ORBITAL IMPLANT
 Promotes orbital growth
 Provides better cosmesis
 Enhances prosthesis motility
 Non integrated(PMMA/ silicon)
 Bio integrated(hydroxyapatite/porous polyethylene)
 Avoided if post operative adjuvant RT is necessary
 Implant vascularisation compromised by RT
 Myoconjunctival technique
Orbital
implants
EXTERNAL BEAM RADIOTHERAPY
 Most commonly employed regional eye-preserving
therapy for this disease was external beam radiation
therapy
 Using a linear accelerator in a hospital radiation therapy
department.
 Standard target doses of radiation to the eye and orbit
are in the range of 40–50 Gy given in multiple fractions
of 150–200 cGy over 4–5 weeks.
 External beam radiation therapy results in highly effective
regression of vascularized retinal tumors.
 Tumor regression have been identified.
 Type I-Calcific avascular mound Type II-prominent
calcification gray-tan fish flesh appearance
 One or more tumors which involve optic disc
 Diffuse vitreal/subretinal seeding
 Prior chemo/local therapy has failed
 Vitreous seeds do not respond well-relatively
hypoxic state
 SIDE EFFECTS OF EBRT
 Cataract-PSCC (6 months after radiation)
 Dry eye
 Radiation neuropathy
 Neovascular glaucoma
 Orbital bone growth arrest
 Non retinoblastoma malignancies
PLAQUE RADIATION THERAPY
 Large but localized in the presence of limited
localized vitreous seeding & does not involve optic
disc/macula
 Plaque radiation therapy -surgical implantation of a
radioactive device (eye plaque) of appropriate size
and strength on the sclera overlying the intraocular
tumor,
 Plaque in place for a sufficient period of time (usually
2–5 days) to provide a predetermined radiation dose
to the apex of the tumor, and subsequent surgical
removal of the plaque.
 The principal isotopes used in radioactive eye
plaques at present are iodine-125 and ruthenium-
106.
 Target dose of 40–45 Gy to the tumor apex is
generally employed. As a result of the physical
dose-distribution -,the base of the tumor always
receives a substantially >apex.
 Orbital tissue –layer of metal on outer surface shields
the emission in that direction
 <16mm basal diameter, < 8 mm thickness
 Notched plaque to protect optic nerve
 To apex-4000-5000cGy
 Sutured to sclera, left in situ-36-72hrs
A.PRETREATMENT
MACULAR
RETINOBLASTOMA
B.POST PLAQUE RT-
REGESSED
Ruthenium
plaque
sutured to
sclera
LASER THERAPY
1. PHOTOCOAGULATION
2. TRANS-PUPILLARY THERMOTHERAPY
PHOTOCOAGULATION
 In photocoagulation, an argon green laser-
instantaneous pronounced whitening of the target
tissues.(4mmx2mm)
 An indirect ophthalmoscope delivery system and
relatively long exposure durations (1 second or
more up to a continuous exposure).
 Ophthalmologist first creates an intense confluent
white chorioretinal coagulation approximately 1–2
mm wide entirely around the retinal tumor.
 Supplementally treats any feeding retinal blood
vessels until they appear to be occluded.
 Treats the tumor directly until it also appears
homogeneously and intensely white.
SIDE EFFECTS
 Transient serous RD
 Retinal vascular occlusion
 Retinal hole
 Retinal traction
 Pre retinal fibrosis
 Large xisual field defect major complication
 CI-active chemoreduction-restricts blood supply so
reduces concentration of chemotherapeutic agent
TRANS PUPILLARY THERMOTHERAPY
 Infrared laser beam 810nm
 Operating microscope/IDO
 Larger spot size 2-3mm
 Till dull white discolouration is produced
 Overlapping spots till homogenous
 Tumor-replaced by chorioretinal atrophy-end point
 Follow up 2-4 weeks
 Extra macular or extrapapillary tumors
CRYOTHERAPY
 Trans-scleral cryotherapy is an obliterative focal
treatment -destroys targeted intraocular tissues by
means of freezing
 Insulated retinal cryoprobe to indent the sclera
overlying the tumor and indirect ophthalmo-scopy to
monitor the position of the indentation in the fundus.
 Once the probe tip is positioned at the site of a
retinal tumor, the ophthalmologist activates the probe
to begin freezing.
 The ice ball that forms -encompass the entire tumor (if the
tumor is small) or a portion of the tumor (if the tumor is larger)
and extend into the overlying vitreous.
 The probe is then deactivated, and the ice ball is allowed to
thaw.
 This cycle is repeated once (double freeze-thaw method) or
twice (triple freeze-thaw method) at each site. If the tumor is
larger than can be encompassed entirely by a single freeze,
Repeated every 2-4 weeks
 Cryo-applied 2-3 hours prior to chemo-increases delivery of
drug across BRB
SIDE EFFECTS
 Transient RD
 Retinal tear
COURSE & OUTCOME
REFERENCES
1. Yanoff Textbook of Ophthalmology 3 rd edition-887-
894
2. Retinoblastoma AIOS series No 25
3. Indian journal of ophthalmology-April 2012
 THANK YOU

Más contenido relacionado

La actualidad más candente (20)

Ocular surface squamous neoplasia(ossn)
Ocular surface squamous neoplasia(ossn)Ocular surface squamous neoplasia(ossn)
Ocular surface squamous neoplasia(ossn)
 
Retinoblastoma
RetinoblastomaRetinoblastoma
Retinoblastoma
 
THYROID EYE DISEASE
THYROID EYE DISEASETHYROID EYE DISEASE
THYROID EYE DISEASE
 
Leukocoria (White Pupillary Reflex)
Leukocoria (White Pupillary Reflex) Leukocoria (White Pupillary Reflex)
Leukocoria (White Pupillary Reflex)
 
Central Retinal Vein Occlsion (CRVO)
Central Retinal Vein Occlsion (CRVO)Central Retinal Vein Occlsion (CRVO)
Central Retinal Vein Occlsion (CRVO)
 
MANAGEMENT OF RETINOBLASTOMA & CURRENT TRENDS
MANAGEMENT OF RETINOBLASTOMA & CURRENT TRENDSMANAGEMENT OF RETINOBLASTOMA & CURRENT TRENDS
MANAGEMENT OF RETINOBLASTOMA & CURRENT TRENDS
 
Orbital Tumour
Orbital Tumour Orbital Tumour
Orbital Tumour
 
Nodule at the limbus
Nodule at the limbusNodule at the limbus
Nodule at the limbus
 
Orbital tumours
Orbital tumoursOrbital tumours
Orbital tumours
 
Retinoblastoma 7th
Retinoblastoma 7thRetinoblastoma 7th
Retinoblastoma 7th
 
Retinoblastoma
RetinoblastomaRetinoblastoma
Retinoblastoma
 
Congenital glaucoma
Congenital glaucomaCongenital glaucoma
Congenital glaucoma
 
Orbital cellulitis
Orbital cellulitisOrbital cellulitis
Orbital cellulitis
 
Hyphema
HyphemaHyphema
Hyphema
 
Anterior uveitis
Anterior uveitisAnterior uveitis
Anterior uveitis
 
Angle Closure Glaucoma
Angle  Closure  GlaucomaAngle  Closure  Glaucoma
Angle Closure Glaucoma
 
Nystagmus
NystagmusNystagmus
Nystagmus
 
Congenital cataract
Congenital cataractCongenital cataract
Congenital cataract
 
Pterygium
PterygiumPterygium
Pterygium
 
Anterior uveitis
Anterior uveitisAnterior uveitis
Anterior uveitis
 

Destacado

Destacado (10)

Retinitis pigmentosa
Retinitis pigmentosaRetinitis pigmentosa
Retinitis pigmentosa
 
Retinoblastoma
RetinoblastomaRetinoblastoma
Retinoblastoma
 
Retinoblastoma
RetinoblastomaRetinoblastoma
Retinoblastoma
 
Enferm. Coats
Enferm. CoatsEnferm. Coats
Enferm. Coats
 
Enfermedad de norrie
Enfermedad de norrieEnfermedad de norrie
Enfermedad de norrie
 
Enfermedad de coats
Enfermedad de coatsEnfermedad de coats
Enfermedad de coats
 
Wilms tumor
Wilms tumorWilms tumor
Wilms tumor
 
Wilm’s tumor
Wilm’s tumorWilm’s tumor
Wilm’s tumor
 
Retinoblastoma
RetinoblastomaRetinoblastoma
Retinoblastoma
 
Breast Cancer.ppt
Breast Cancer.pptBreast Cancer.ppt
Breast Cancer.ppt
 

Similar a Retinoblastoma

Retinoblastoma
RetinoblastomaRetinoblastoma
Retinoblastomaairwave12
 
Retinoblastoma : Dr Shylesh B Dabke
Retinoblastoma : Dr Shylesh B DabkeRetinoblastoma : Dr Shylesh B Dabke
Retinoblastoma : Dr Shylesh B DabkeShylesh Dabke
 
RETINOBLASTOMA.pptx
RETINOBLASTOMA.pptxRETINOBLASTOMA.pptx
RETINOBLASTOMA.pptxManjuM74
 
Management Of Retinoblastoma
Management Of Retinoblastoma  Management Of Retinoblastoma
Management Of Retinoblastoma Dr Manas Dubey
 
Retinoblastoma .pptx
Retinoblastoma .pptxRetinoblastoma .pptx
Retinoblastoma .pptxRituRMenon
 
Retinoblastoma - Diagnosis and Management Presentation
Retinoblastoma - Diagnosis and Management PresentationRetinoblastoma - Diagnosis and Management Presentation
Retinoblastoma - Diagnosis and Management Presentationdocumesh
 
Orbital imaging iii
Orbital imaging iiiOrbital imaging iii
Orbital imaging iiiEhab Elftouh
 
VITREOUS AND RETINA PEDIATRIC OCULAR DIESEASES.pptx
VITREOUS AND RETINA PEDIATRIC OCULAR DIESEASES.pptxVITREOUS AND RETINA PEDIATRIC OCULAR DIESEASES.pptx
VITREOUS AND RETINA PEDIATRIC OCULAR DIESEASES.pptxreshmasu
 
PEDIATRIC EMBRYONAL TUMOURS - UPDATE
PEDIATRIC EMBRYONAL TUMOURS - UPDATE PEDIATRIC EMBRYONAL TUMOURS - UPDATE
PEDIATRIC EMBRYONAL TUMOURS - UPDATE DrAarti Tyagi
 
Retinoblastoma (Bsc. optometry 2nd year KUHS)Exam view point
Retinoblastoma (Bsc. optometry 2nd year KUHS)Exam view pointRetinoblastoma (Bsc. optometry 2nd year KUHS)Exam view point
Retinoblastoma (Bsc. optometry 2nd year KUHS)Exam view pointNavmii
 

Similar a Retinoblastoma (20)

Retinoblastoma
RetinoblastomaRetinoblastoma
Retinoblastoma
 
Retinoblastoma : Dr Shylesh B Dabke
Retinoblastoma : Dr Shylesh B DabkeRetinoblastoma : Dr Shylesh B Dabke
Retinoblastoma : Dr Shylesh B Dabke
 
Retinoblastoma
RetinoblastomaRetinoblastoma
Retinoblastoma
 
Retinoblastoma
RetinoblastomaRetinoblastoma
Retinoblastoma
 
RETINOBLASTOMA.pptx
RETINOBLASTOMA.pptxRETINOBLASTOMA.pptx
RETINOBLASTOMA.pptx
 
Phacomatosis
Phacomatosis Phacomatosis
Phacomatosis
 
Intraocular tumors
Intraocular tumorsIntraocular tumors
Intraocular tumors
 
Management Of Retinoblastoma
Management Of Retinoblastoma  Management Of Retinoblastoma
Management Of Retinoblastoma
 
Retinoblastoma .pptx
Retinoblastoma .pptxRetinoblastoma .pptx
Retinoblastoma .pptx
 
Retinoblastoma
RetinoblastomaRetinoblastoma
Retinoblastoma
 
Retinoblastoma - Diagnosis and Management Presentation
Retinoblastoma - Diagnosis and Management PresentationRetinoblastoma - Diagnosis and Management Presentation
Retinoblastoma - Diagnosis and Management Presentation
 
Orbital imaging iii
Orbital imaging iiiOrbital imaging iii
Orbital imaging iii
 
Neuroblastoma
NeuroblastomaNeuroblastoma
Neuroblastoma
 
VITREOUS AND RETINA PEDIATRIC OCULAR DIESEASES.pptx
VITREOUS AND RETINA PEDIATRIC OCULAR DIESEASES.pptxVITREOUS AND RETINA PEDIATRIC OCULAR DIESEASES.pptx
VITREOUS AND RETINA PEDIATRIC OCULAR DIESEASES.pptx
 
PEDIATRIC EMBRYONAL TUMOURS - UPDATE
PEDIATRIC EMBRYONAL TUMOURS - UPDATE PEDIATRIC EMBRYONAL TUMOURS - UPDATE
PEDIATRIC EMBRYONAL TUMOURS - UPDATE
 
Retinoblastoma
RetinoblastomaRetinoblastoma
Retinoblastoma
 
Genedermatosis
GenedermatosisGenedermatosis
Genedermatosis
 
retinoblastoma 2.pptx
retinoblastoma 2.pptxretinoblastoma 2.pptx
retinoblastoma 2.pptx
 
Retinoblastoma.pptx
Retinoblastoma.pptxRetinoblastoma.pptx
Retinoblastoma.pptx
 
Retinoblastoma (Bsc. optometry 2nd year KUHS)Exam view point
Retinoblastoma (Bsc. optometry 2nd year KUHS)Exam view pointRetinoblastoma (Bsc. optometry 2nd year KUHS)Exam view point
Retinoblastoma (Bsc. optometry 2nd year KUHS)Exam view point
 

Más de SSSIHMS-PG

Duanes retraction syndrome ..
Duanes retraction syndrome ..Duanes retraction syndrome ..
Duanes retraction syndrome ..SSSIHMS-PG
 
Visual evoked potential
Visual evoked potentialVisual evoked potential
Visual evoked potentialSSSIHMS-PG
 
Iridocorneal endothelial syndrome
Iridocorneal endothelial syndromeIridocorneal endothelial syndrome
Iridocorneal endothelial syndromeSSSIHMS-PG
 
Optic neuritis
Optic neuritisOptic neuritis
Optic neuritisSSSIHMS-PG
 
Supranuclear disorders of ocular motility
Supranuclear disorders of ocular motilitySupranuclear disorders of ocular motility
Supranuclear disorders of ocular motilitySSSIHMS-PG
 
Anatomy and physiology of cornea
Anatomy and physiology of corneaAnatomy and physiology of cornea
Anatomy and physiology of corneaSSSIHMS-PG
 
Congenital glaucomas
Congenital glaucomasCongenital glaucomas
Congenital glaucomasSSSIHMS-PG
 
neovascular glaucoma
neovascular glaucomaneovascular glaucoma
neovascular glaucomaSSSIHMS-PG
 
Optics of ametropia
Optics of ametropiaOptics of ametropia
Optics of ametropiaSSSIHMS-PG
 
Miotics and mydriatics
Miotics and mydriaticsMiotics and mydriatics
Miotics and mydriaticsSSSIHMS-PG
 
Refraction using a phoropter
Refraction using a phoropterRefraction using a phoropter
Refraction using a phoropterSSSIHMS-PG
 
Slit lamp biomicroscopy
Slit lamp biomicroscopySlit lamp biomicroscopy
Slit lamp biomicroscopySSSIHMS-PG
 
Uveitic glaucoma
Uveitic glaucomaUveitic glaucoma
Uveitic glaucomaSSSIHMS-PG
 
Complications of squint sx
Complications of squint sxComplications of squint sx
Complications of squint sxSSSIHMS-PG
 
HRT and GDx VCC
HRT and GDx VCCHRT and GDx VCC
HRT and GDx VCCSSSIHMS-PG
 
Vitreomacular traction
Vitreomacular tractionVitreomacular traction
Vitreomacular tractionSSSIHMS-PG
 
Angle recession glaucoma
Angle recession glaucomaAngle recession glaucoma
Angle recession glaucomaSSSIHMS-PG
 
Hvf progession
Hvf progessionHvf progession
Hvf progessionSSSIHMS-PG
 
Pigment dispersion syndrome
Pigment dispersion syndromePigment dispersion syndrome
Pigment dispersion syndromeSSSIHMS-PG
 

Más de SSSIHMS-PG (20)

Duanes retraction syndrome ..
Duanes retraction syndrome ..Duanes retraction syndrome ..
Duanes retraction syndrome ..
 
Visual evoked potential
Visual evoked potentialVisual evoked potential
Visual evoked potential
 
Iridocorneal endothelial syndrome
Iridocorneal endothelial syndromeIridocorneal endothelial syndrome
Iridocorneal endothelial syndrome
 
Optic neuritis
Optic neuritisOptic neuritis
Optic neuritis
 
Supranuclear disorders of ocular motility
Supranuclear disorders of ocular motilitySupranuclear disorders of ocular motility
Supranuclear disorders of ocular motility
 
Anatomy and physiology of cornea
Anatomy and physiology of corneaAnatomy and physiology of cornea
Anatomy and physiology of cornea
 
Congenital glaucomas
Congenital glaucomasCongenital glaucomas
Congenital glaucomas
 
neovascular glaucoma
neovascular glaucomaneovascular glaucoma
neovascular glaucoma
 
Optics of ametropia
Optics of ametropiaOptics of ametropia
Optics of ametropia
 
Miotics and mydriatics
Miotics and mydriaticsMiotics and mydriatics
Miotics and mydriatics
 
Refraction using a phoropter
Refraction using a phoropterRefraction using a phoropter
Refraction using a phoropter
 
Slit lamp biomicroscopy
Slit lamp biomicroscopySlit lamp biomicroscopy
Slit lamp biomicroscopy
 
Uveitic glaucoma
Uveitic glaucomaUveitic glaucoma
Uveitic glaucoma
 
Complications of squint sx
Complications of squint sxComplications of squint sx
Complications of squint sx
 
HRT and GDx VCC
HRT and GDx VCCHRT and GDx VCC
HRT and GDx VCC
 
Vitreomacular traction
Vitreomacular tractionVitreomacular traction
Vitreomacular traction
 
Angle recession glaucoma
Angle recession glaucomaAngle recession glaucoma
Angle recession glaucoma
 
Trachoma
TrachomaTrachoma
Trachoma
 
Hvf progession
Hvf progessionHvf progession
Hvf progession
 
Pigment dispersion syndrome
Pigment dispersion syndromePigment dispersion syndrome
Pigment dispersion syndrome
 

Último

SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdfSGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdfHongBiThi1
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.kishan singh tomar
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfHongBiThi1
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.whalesdesign
 
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdfSGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdfHongBiThi1
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024EwoutSteyerberg1
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentsaileshpanda05
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxMAsifAhmad
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaSujoy Dasgupta
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfHongBiThi1
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project reportNARMADAPETROLEUMGAS
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.pptRamDBawankar1
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptxWINCY THIRUMURUGAN
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .Mohamed Rizk Khodair
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationMedicoseAcademics
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxkomalt2001
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets barmohitRahangdale
 

Último (20)

SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdfSGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.
 
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdfSGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024
 
American College of physicians ACP high value care recommendations in rheumat...
American College of physicians ACP high value care recommendations in rheumat...American College of physicians ACP high value care recommendations in rheumat...
American College of physicians ACP high value care recommendations in rheumat...
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing student
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
 
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project report
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
 
Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptx
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets bar
 

Retinoblastoma

  • 2. HISTORY  First mentioned by Petras Pawius in Amsterdam -1597.  James Wardrop- scottish surgeon first recommended enucleation for saving lives - 1809.  Verhoeff -origin from undifferentiated retinal cells, named retinoblastoma in 1900’s.  American Ophthalmology Society first adopted the term retinoblastoma in 1926.
  • 3. INTRODUCTION  Primary malignant neoplasm of the retina that arises from immature retinal cells  It is the most common primary intraocular malignancy of childhood in all racial groups  Seventh MC tumor of childhood  Unifocal/multifocal.  Unilateral (70%) or bilateral (30%).  Sporadic (94%) or familial (6%).  Non hereditary (50-60%) or hereditary (40- 50%).
  • 4. EPIDEMIOLOGY  Cumulative lifetime incidence-1 in 15000  Annual incidence –highest in first few months of life  Yearly incidence decreases steadily  Extremely low by 6 years of age.  Rarely diagnosed congenitally or even within the first 3 months of life, except in familial cases.  Median age at the time of diagnosis is approximately 12 months  B/l retinoblastoma (12 months )>18m in u/l case  Retinoblastoma affects boys and girls with equal frequency and has no known racial predilection.
  • 5. Frequency is shown as a function of age at diagnosis in subgroups of unilateral versus bilateral disease.
  • 6. INHERITANCE  60–70% of retinoblastoma – unilateral  30–40% are bilateral.  In unilateral cases, only a single tumor is usually present in the affected eye.  In bilateral cases, multifocal tumors in both eyes are the rule. Retinoblastoma is generally a sporadic condition (i.e., no previously affected family members exist).
  • 7.  Sporadic form of retinoblastoma are affected unilaterally.  A small number -have a prior family history of retinoblastoma-one of the parents is probably a survivor of the disease.  Transmission of the disease in such families follows genetic rules of autosomal dominant inheritance.
  • 9. GENETICS  Loss or inactivation of both normal alleles of the retinoblastoma gene  DNA sequence localized to a small segment of the long arm (the q14 region) of chromosome 13  The timing of the loss or inactivation of the two normal alleles  germinal (i.e., can be inherited by the offspring of an affected person)  somatic (i.e., cannot be inherited by the offspring of an affected person)
  • 10.  In germinal retinoblastoma- at least one normal allele must be lost or inactivated prior to the first mitotic division of embryogenesis  Sperm or the egg contains defective DNA from an affected or carrier parent or develops that defect by means of spontaneous mutation prior to fertilization.  In somatic retinoblastoma, both alleles are present and active beyond the stage of the fertilized egg- but subsequent mutations occur to delete or inactivate both alleles in at least one immature retinal cell (retinoblast).
  • 11. For retinoblastoma to occur both the allels have to be deleted  If only one allel is deleted it is called 13q deletion syndrome
  • 13.  In germinal mutaion , which is inherited ,  First hit occurs before fertilisation & affects all types of cell  2nd hit occurs in somatic retinal cells leads to RB.  2nd ry tumours like osteosarcoma are seen in familial cases  But in sporadic mutation both hits occurs during development of retina , so it affects only retina , no 2nd ry tumours…
  • 14. Individuals who inherit a mutation in the retinoblastoma gene are heterozygous for the mutation in all cells of the body. The “second hit” to the remaining normal copy of the gene occurs in a developing retinal cell and leads to tumor formation
  • 15. MOLECULAR PATHOGENESIS  RB1 protein: cell cycle regulator, checkpoint between G1 & S-phase.  Key factor in RB protien functioning is the phosphorylation status.  Normally unphosphorylated and suppresses entry into S- phase by binding to E2F (transcription apparatus).  Phosphorylation by cyclin/cdk’s abolishes inhibition & causes dissociation of E2F which binds to DNA & promotes progression through cell cycle.
  • 18. CLINICAL MANIFESTATIONS MANIFESTATION PERCENTAGE LEUCOCORIA 56% STRABISMUS 20% RED PAINFUL EYE 7% POOR VISION 5% ASYMPTOMATIC 3% ORBITAL CELLULITIS 3% UNILATERAL MYDRIASIS 2% HETEROCHROMIA IRIDID 1% HYPHEMA 1%
  • 23. CLINICAL MANIFESTATIONS  Clinical presentation depends on the stage of the disease  Early likely to be missed- unless IDO is performed  Translucent white fluffy retinal mass  Strabismus- if tumor involves macula/reduced visual acuity  Moderately advanced-leucocoria reflection of light by white mass in the fundus
  • 24. THREE MANIFESTATIONS  Endophytic: grows in to vitreous cavity. Yellow white mass fills vitreous cavity & vitreous seeds. Retinal vessels –not seen on the surface  Exophytic: tumor towards subretinal space. Retinal detachment, retinal vessels are seen over tumor  Diffuse infiltrating tumor: diffusely involve retina placoid thickness of the retina. Older children delay in diagnosis
  • 25.  Advanced- proptosis secondary to optic nerve/ orbital extension  Orbital extension-scleral emissary veins  Atypical manifestations: -pseudohypopyon -spontaneous hyphema -vitreous hemorrhage -phthisis bulbli -preseptal/orbital cellulits
  • 27. PRESENTATION  White round oval dome shaped retinal masses  Attract retinal BVs  Very small tumors - Translucent thickenings  Larger tumors- non rhegmatogenous RD  Tumors – extend via RPE- exophytic - into vitreous - endophytic -generalised thickening-Infiltrating Retinoblastoma  Ocassionally stops progressing-Retinoma  Severe necrosis-Phthisis
  • 28. Typical appearance of intraretinal retinoblastoma. Opaque, yellow-white macular tumor fed and drained by dilated, tortuous retinal blood vessels.
  • 29. RETINOMA-spontaneously arrested retinoblastoma Limited vascularity Greyish-white Speckled Surrounding chorio-retinal atrophy RPE hypertrophy
  • 30. PATHOLOGY  Malignant neuroepithelial cells (retinoblasts)- arise within the immature retina  The retinoblasts -large basophilic nucleus and scanty cytoplasm.  Cellular necrosis & intralesional calcification- larger tumors.  Tissue differentiation occurs,- producing Flexner-Wintersteiner rosettes or Homer Wright rosettes  Photoreceptor differentiation of individual retinoblasts (fleurettes) may also be observed  Retinoblastoma - tendency to invade the optic nerve and choroid - extend out of the globe via either the optic nerve or the scleral emissary canals.  Retinomas show such tumors to be composed entirely of benign- appearing neuronal cells with photoreceptor differentiation, most notably in the form of fleurettes.  Pseudorosettes-tumor cells around Blood vessels
  • 31. PATHOLOGY Flexner Wintersteiner rosettes -columnar cells around a central lumen -also seen in medulloepithelioma Homer Wright -rosettes around a central neuromuscular core -neuroblastoma, medulloepithelioma, medulloblastomas Fleurettes Tumor cells with pear shaped eosinophilic processes projecting through
  • 32. DIFFERENTIAL DIAGNOSIS Differential Diagnosis of Leukokoria Coats’ disease Persistent hyperplastic primary vitreous Ocular toxocariasis Cicatricial retinopathy of prematurity Familial exudative vitreoretinopathy Incontinentia pigmenti retinopathy Norrie’s disease Differential Diagnosis of Vitreous Seeds Pars planitis (intermediate uveitis) Microbial endophthalmitis or retinitis Leukemic infiltration Differential Diagnosis of Discrete Retinal Tumors Astrocytoma of retina Medulloepithelioma Retinal capillary hemangioma
  • 34. TO BE CONTINUED IN NEXT CLASS STAGING DAIGNOSIS TREATMENT
  • 39. DIAGNOSIS  ULTRASONOGRAPHY  >10-15mm, multiple foci of calcification  Shadows the sclera & orbital soft tissue  On reducing the gain-reflection persist  Demonstrates a mass more echogenic than vitreous on B scan highly reflective intrinsic echoes of fine calcifications-Ascan  RD in exophytic tumors  Accuracy-80% limited by vitreous opacities & RD  Limited evaluation of medial and lateral extension  Colour Doppler: displays normal & tumor vasculature & differentiates subretinal or choroidalh’he from neoplasms
  • 40. B-scan ultrasonography of retinoblastoma. Solid, posterior intraocular mass contains strong particulate reflections attributable to intralesional calcification.
  • 41. INDIRECT OPHTHALMOSCOPY  Dilated fundus examination under anaesthesia  IOP and anterior segment-neovascularisation, pseudohypopyon, hyphema and signs of inflammation  Bilateral fundus examination-360◦ scleral depression  Ret Cam: wide angle fundus camera –documenting and monitoring response
  • 42. CT SCAN  Bright on CT scan  Infiltrating Retinoblastoma-tumor multicentricity , extensive seeding into vitreous MRI  Most useful for evaluating sellar/parasellar  Rule out- ectopic intracranial RB  Studying optic nerve & soft tissues
  • 43. Computed tomography of bilateral intraocular retinoblastoma. Intraocular masses appear bright because of intralesional calcification.
  • 45. FFA  Not usually performed  Rapid filling of feeder vessel-intraretinal vasculature- draining of efferent vein  Intralesional capillaries-leak fluoroscein
  • 46. SYSTEMIC EVALUATON  Germinal retinoblastoma have a strong tendency to develop non-retinoblastoma malignancies  Primary nonretinoblastoma intracranial malignancy - either a pineoblastoma or an ectopic intracranial retinoblastoma- most common neoplasm -somnolence, headache, and other neurological symptoms.  Central nervous system -solid tumor that involves the suprasellar or parasellar regions of the brain  Ophthalmoscopy frequently reveals papilledema- referred to as trilateral retinobloma, seed the cerebrospinal fluid and thereby spawn implantation tumors along the spinal cord. This malignancy is usually fatal
  • 47. Sarcomas of bone and soft tissues- most frequent nonretinoblastoma malignancies Oculo-orbital external beam radiation therapy- < age of 1 year appears-increase the likelihood that such tumors will occur in the field. Syndrome of multiple congenital anomalies attributed to a major deletion (13q deletion syndrome by karyotype analysis.
  • 48. BASELINE SYSTEMIC EVALUATION IN RETINOBLASTOMA  Complete pediatric history and physical examination  Blood for complete blood count (CBC)  MRI or CT of brain, especially in bilateral or familial cases to look for ectopic intracranial retinoblastoma  Lumbar puncture for cerebrospinal fluid analysis[∗]  Bone marrow aspiration or biopsy[∗]  Bone scan[∗]
  • 50. INTERNATIONAL CLASSIFICATION (SHIELDS)  Group A Small tumor Retinoblastoma <3mm in size in basal dimension/thickness  Group B Larger tumor Retinoblastoma>3mm basal diameter/ thickness Macular location<3mm to foveola Juxtapapillary location <1.5mm to the disc Clear subretinal fluid<3mm from the margin  Group C Focal seeds c1-subretinal seeds<3mm c2 –vitreous seeds <3mm c3-both subretinal and vitreous seeds
  • 51.  Group D Diffuse seeds D1-subretinal seeds>3mm D2-vitreous seeds >3mm D3-Both  Group E Extensive Retinoblastoma occupying>50% of the globe neovascular glaucoma opaque media-hhge- AC/PC/Subretnal space Invasion of postlaminar optic nerve/ choroid/sclera/orbit/AC
  • 55. MANAGEMENT  Primary goal-save life  Salvage of the organ and function-secondary and tertiary  Multidisciplinary approach  Individualised –depends on 1. Age 2. Laterality 3. Location 4. Staging 5. Systemic condition 6. Overall progression 7. Cost effectiveness
  • 56. CURRENT SUGGESTED PROTOCOL  A Intraocular tumor- international classification group-A-C U/L or B/L 1. Focal-cryotherapy/transpupillary thermotherapy tumors<3mm in visually non crucial areas 2. Standard 6 cycle chemoreduction and focal therapy for larger tumors and in visually crucial areas 3. Defer focal therapy for 6 cycles for tumors in macular and juxtapapillary areas-transpupillary thermotherapy/plaque RT in juxtapapillary and macula 4. Focal therapy small residual tumors, plaque RT, EBRT -> 12 months.large.B/L and enucleation if U/L
  • 57.  B. Intraocular tumor, Group D U/L or B/L 1. High dose chemotherapy/aggressive focal therapy 2. Periocular carboplatin –vitreous seeds 3. Primary enucleation-U/L- esp with no visual prognosis
  • 58.  C. Group E U/L or B/L 1. Primary enucleation 2. Evaluate histopathology for high risk factors
  • 59.  D. High risk factors on HPE- Stage 2 1. Baseline systemic evaluation for metastasis 2. Standard 6 cycle adjuvant therapy 3. High dose adjuvant chemotherapy + orbital EBRT- with scleral infiltration, extraocular extension, optic nerve extension
  • 60.  E. Extraocular tumor-Stage 3A 1. Baseline systemic evaluation for metastases 2. High dose chemotherapy-3-6 cycles followed by enucleation/extended enucleation, EBRT, high dose chemo 12 cycles
  • 61.  F. Regional LN metastasis Stage 3B 1. Baseline evaluation for systemic metastasis 2. Neck dissection, high dose chemotherapy for 6 cycles, followed by EBRT and high dose chemotherapy-12 cycles
  • 62.  G. Hematogenous /CNS metastasis-Stage 4 1. Palliative therapy 2. High dose chemotherapy –BM rescue 3. High dose chemotherapy- intrathecal chemotherapy for CNS metastases
  • 63. TREATMENT  TREATMENT OPTIONS FOR INTRAOCULAR RETINOBLASTOMA Intravenous chemotherapy Enucleation Radiation therapy • External beam radiation therapy • Plaque radiotherapy Laser therapy • Photocoagulation • Transpupillary thermotherapy (TTT) Cryotherapy Observation (for spontaneously arrested retinoblastoma, retinoma)
  • 64. CHEMOTHERAPY  Chemotherapy is currently the primary therapeutic option -bilateral retinoblastoma.  Initial treatment - unilateral disease -affected eye is salvageable.  Most common chemotherapeutic regimen -a combination of carboplatin, etoposide or a related drug, and vincristine (CEV regimen). In some centers, cyclosporine is added to this regimen to reduce the multidrug resistance that occurs in many retinoblastomas.  Chemotherapy must be supervised by a pediatric oncologist who is familiar with the side effects and complications of the drugs and can monitor the child closely during treatment.  Cyclic treatment every 3–4 weeks for six or more cycles.  Most intraocular retinoblastoma lesions (including intravitreal and
  • 65.  Partially regressed tumors -still viable following the second cycle of chemotherapy / any new tumors during the course of chemotherapy must be treated by obliterative local therapies such as cryotherapy, laser therapy, and episcleral plaque radiation therapy.  Periocular carboplatin injections are currently being evaluated as an adjunct to intravenous chemotherapy in selected cases.  Residual or recurrent intravitreal and subretinal seeds following chemotherapy and local treatments usually require external beam radiation therapy if the eye is to be salvaged.
  • 66. Chemotherapy for retinoblastoma. (A) Pretreatment appearance of macular retinoblastoma. (B) Same lesion after two cycles of chemotherapy using vincristine, etoposide, and carboplatin.
  • 67. ENUCLEATION  Enucleation remains an important therapeutic option for this disease.  Children who have unilateral advanced intraocular disease.  Enucleation is sometimes recommended for both eyes in children who have bilateral far-advanced disease not amenable to any eye-preserving therapy and for the more severely affected eye in markedly asymmetrical bilateral cases.  If enucleation is performed, the ophthalmic surgeon should attempt to obtain a long section of the optic nerve during surgery.
  • 68.  The principal route of exit of tumor cells from the eye is along the optic nerve. Prior pathological studies have shown that enucleation is usually curative in retinoblastoma if an optic nerve section longer than 5 mm is obtained with the globe.[15] If possible, the ophthalmic surgeon should attempt to obtain an optic nerve section 10–15 mm long in every case.  Insertion of an orbital implant at the time of enucleation appears to be appropriate except when there is a strong likelihood of residual tumor in the orbit..
  • 69. SPECIAL CONSIDERATIONS FOR ENUCLEATION  A Minimal manipulation  B Avoid perforation of the eye  C Harvest long >15 mm optic nerve stump  D inspect the enucleated eye for macroscopic extraocular extension & optic nerve involvement  E Harvest fresh tissue for genetic studies  F Place a primary implant  G Avoid biointegrated implant if postoperative radiotherapy is necessary
  • 70. ORBITAL IMPLANT  Promotes orbital growth  Provides better cosmesis  Enhances prosthesis motility  Non integrated(PMMA/ silicon)  Bio integrated(hydroxyapatite/porous polyethylene)  Avoided if post operative adjuvant RT is necessary  Implant vascularisation compromised by RT  Myoconjunctival technique
  • 72. EXTERNAL BEAM RADIOTHERAPY  Most commonly employed regional eye-preserving therapy for this disease was external beam radiation therapy  Using a linear accelerator in a hospital radiation therapy department.  Standard target doses of radiation to the eye and orbit are in the range of 40–50 Gy given in multiple fractions of 150–200 cGy over 4–5 weeks.  External beam radiation therapy results in highly effective regression of vascularized retinal tumors.  Tumor regression have been identified.  Type I-Calcific avascular mound Type II-prominent calcification gray-tan fish flesh appearance
  • 73.  One or more tumors which involve optic disc  Diffuse vitreal/subretinal seeding  Prior chemo/local therapy has failed  Vitreous seeds do not respond well-relatively hypoxic state
  • 74.  SIDE EFFECTS OF EBRT  Cataract-PSCC (6 months after radiation)  Dry eye  Radiation neuropathy  Neovascular glaucoma  Orbital bone growth arrest  Non retinoblastoma malignancies
  • 75. PLAQUE RADIATION THERAPY  Large but localized in the presence of limited localized vitreous seeding & does not involve optic disc/macula  Plaque radiation therapy -surgical implantation of a radioactive device (eye plaque) of appropriate size and strength on the sclera overlying the intraocular tumor,  Plaque in place for a sufficient period of time (usually 2–5 days) to provide a predetermined radiation dose to the apex of the tumor, and subsequent surgical removal of the plaque.
  • 76.  The principal isotopes used in radioactive eye plaques at present are iodine-125 and ruthenium- 106.  Target dose of 40–45 Gy to the tumor apex is generally employed. As a result of the physical dose-distribution -,the base of the tumor always receives a substantially >apex.  Orbital tissue –layer of metal on outer surface shields the emission in that direction
  • 77.  <16mm basal diameter, < 8 mm thickness  Notched plaque to protect optic nerve  To apex-4000-5000cGy  Sutured to sclera, left in situ-36-72hrs
  • 80. LASER THERAPY 1. PHOTOCOAGULATION 2. TRANS-PUPILLARY THERMOTHERAPY
  • 81. PHOTOCOAGULATION  In photocoagulation, an argon green laser- instantaneous pronounced whitening of the target tissues.(4mmx2mm)  An indirect ophthalmoscope delivery system and relatively long exposure durations (1 second or more up to a continuous exposure).  Ophthalmologist first creates an intense confluent white chorioretinal coagulation approximately 1–2 mm wide entirely around the retinal tumor.  Supplementally treats any feeding retinal blood vessels until they appear to be occluded.  Treats the tumor directly until it also appears homogeneously and intensely white.
  • 82. SIDE EFFECTS  Transient serous RD  Retinal vascular occlusion  Retinal hole  Retinal traction  Pre retinal fibrosis  Large xisual field defect major complication  CI-active chemoreduction-restricts blood supply so reduces concentration of chemotherapeutic agent
  • 83. TRANS PUPILLARY THERMOTHERAPY  Infrared laser beam 810nm  Operating microscope/IDO  Larger spot size 2-3mm  Till dull white discolouration is produced  Overlapping spots till homogenous  Tumor-replaced by chorioretinal atrophy-end point  Follow up 2-4 weeks  Extra macular or extrapapillary tumors
  • 84. CRYOTHERAPY  Trans-scleral cryotherapy is an obliterative focal treatment -destroys targeted intraocular tissues by means of freezing  Insulated retinal cryoprobe to indent the sclera overlying the tumor and indirect ophthalmo-scopy to monitor the position of the indentation in the fundus.  Once the probe tip is positioned at the site of a retinal tumor, the ophthalmologist activates the probe to begin freezing.
  • 85.  The ice ball that forms -encompass the entire tumor (if the tumor is small) or a portion of the tumor (if the tumor is larger) and extend into the overlying vitreous.  The probe is then deactivated, and the ice ball is allowed to thaw.  This cycle is repeated once (double freeze-thaw method) or twice (triple freeze-thaw method) at each site. If the tumor is larger than can be encompassed entirely by a single freeze, Repeated every 2-4 weeks  Cryo-applied 2-3 hours prior to chemo-increases delivery of drug across BRB
  • 86. SIDE EFFECTS  Transient RD  Retinal tear
  • 88. REFERENCES 1. Yanoff Textbook of Ophthalmology 3 rd edition-887- 894 2. Retinoblastoma AIOS series No 25 3. Indian journal of ophthalmology-April 2012